Skip to main content
logo
Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
5.55
+0.46 (9.04%)
At close: Sep 18, 2025, 4:00 PM EDT
5.71
+0.16 (2.88%)
After-hours: Sep 18, 2025, 6:02 PM EDT

Entrada Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 20202019
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Market Capitalization
197612503424534-
Upgrade
Market Cap Growth
-52.66%21.70%18.72%-20.71%--
Upgrade
Enterprise Value
-105224219236610-
Upgrade
Last Close Price
5.0917.2915.0913.5217.12-
Upgrade
PE Ratio
-9.33----
Upgrade
PS Ratio
2.632.903.90---
Upgrade
PB Ratio
0.481.432.081.991.79-
Upgrade
P/TBV Ratio
0.511.432.081.991.79-
Upgrade
P/FCF Ratio
--3.75---
Upgrade
P/OCF Ratio
--3.60---
Upgrade
EV/Sales Ratio
-1.061.69---
Upgrade
EV/EBITDA Ratio
-4.41----
Upgrade
EV/EBIT Ratio
-4.77----
Upgrade
EV/FCF Ratio
--1.63---
Upgrade
Debt / Equity Ratio
0.140.140.280.12--
Upgrade
Debt / EBITDA Ratio
-0.924.68---
Upgrade
Debt / FCF Ratio
--0.51---
Upgrade
Asset Turnover
0.150.420.36---
Upgrade
Quick Ratio
18.0510.782.268.6243.3211.62
Upgrade
Current Ratio
18.6411.152.339.5544.4611.89
Upgrade
Return on Equity (ROE)
-18.13%19.56%-2.94%-37.01%-30.19%-93.94%
Upgrade
Return on Assets (ROA)
-11.66%5.90%-0.55%-21.79%-18.29%-53.97%
Upgrade
Return on Capital (ROIC)
-12.94%7.36%-0.72%-22.63%-18.86%-59.03%
Upgrade
Return on Capital Employed (ROCE)
-9.70%----
Upgrade
Earnings Yield
-37.72%10.72%-1.33%-22.33%-9.57%-
Upgrade
FCF Yield
-65.08%-7.30%26.68%-22.82%-10.38%-
Upgrade
Buyback Yield / Dilution
-19.72%-18.01%-5.62%-399.27%-467.09%-18.45%
Upgrade
Updated Aug 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q